Remove about programs-policies grants competitive-grants
article thumbnail

REGN-COV2 Independent Data Monitoring Committee Recommends Holding Enrollment in Hospitalized Patients with High Oxygen Requirements and Continuing Enrollment in Patients with Low or No Oxygen Requirements

The Pharma Data

About the REGN-COV2 Trial in Hospitalized Patients. About REGN-COV2 REGN-COV2 is a combination of two monoclonal antibodies (REGN10933 and REGN10987) and was designed specifically to block infectivity of SARS-CoV-2, the virus that causes COVID-19. Cohort 1A: patients not requiring oxygen. Cohort 2: patients on high-flow oxygen.

article thumbnail

VERQUVO® (vericiguat) Approved in the European Union

The Pharma Data

European Approval Granted to Bayer Marks Another Important Milestone for VERQUVO. About VERQUVO ® (vericiguat) tablets for once daily oral use (2.5 About the Worldwide Collaboration Between Bayer and Merck. The vericiguat program is being co-developed by Bayer and Merck. About Merck. KENILWORTH, N.J.–(BUSINESS

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

New England Journal of Medicine Publishes Positive Initial Regeneron Antibody Cocktail Results in Non-hospitalized Patients with COVID-19

The Pharma Data

patients under an Emergency Use Authorization, and we also continue a robust clinical development program.” Data from the Phase 1/2/3 clinical trial supported an Emergency Use Authorization for casirivimab and imdevimab administered together, granted by the U.S. One anaphylactic reaction was reported in the clinical program.

article thumbnail

Regeneron’s COVID-19 Outpatient Trial Prospectively Demonstrates that REGN-COV2 Antibody Cocktail Significantly Reduced Virus Levels and Need for Further Medical Attention

The Pharma Data

About REGN-COV2 REGN-COV2 is a combination of two monoclonal antibodies (REGN10933 and REGN10987) and was designed specifically to block infectivity of SARS-CoV-2, the virus that causes COVID-19. For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

article thumbnail

Amgen Reports Second Quarter 2021 Financial Results

The Pharma Data

For comparability of results to the prior year, non-GAAP net income and non-GAAP EPS amounts for 2020 have been revised to reflect the update to our non-GAAP policy that excludes gains and losses on certain equity investments. Going forward, we expect increased competition to result in further declines in net selling price. In the U.S.,

Sales 52
article thumbnail

Regeneron Announces Encouraging Initial Data from COVID-19 Antibody Cocktail Trial in Hospitalized Patients on Low-flow Oxygen

The Pharma Data

29, 2020 /PRNewswire/ — Phase 3 program in hospitalized patients to continue based on passing futility analysis on ability to reduce incidence of death or mechanical ventilation. In November , the Regeneron antibody cocktail was granted an Emergency Use Authorization (EUA) by the U.S. TARRYTOWN, N.Y. , high dose, 0.9% In the U.S.

article thumbnail

Lynparza (olaparib) Receives Health Canada Approval for the Treatment of BRCA or ATM Gene-Mutated Metastatic Castration-Resistant Prostate Cancer

The Pharma Data

The Notice of Compliance was granted under priority review and marks the first Health Canada approval of a PARP inhibitor in prostate cancer. About Lynparza (olaparib) Lynparza was the first oral (PARP) inhibitor approved in Canada. . MISSISSAUGA, ON , Nov. ” .

Gene 52